



## WHAT IF YOU COULD HELP PREVENT CERTAIN HPV-RELATED CANCERS AND DISEASES WITH A VACCINE?

An estimated **75% of sexually active Canadians** will have at least one HPV infection in their lifetime.

For the following indication, GARDASIL®9 has been approved **with conditions**. This means it has passed Health Canada's review and can be bought and sold in Canada, but the manufacturer has agreed to complete more studies to make sure the vaccine works the way it should. For more information, talk to your healthcare professional.

GARDASIL®9, a vaccine (injection/shot) indicated for individuals 9 through 45 years of age for the prevention of infection caused by the Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 and the following diseases associated with the HPV types included in the vaccine: certain head and neck cancers, such as throat and back of mouth cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.

For the following indications, GARDASIL®9 has been approved without conditions. This means it has passed Health Canada's review and can be bought and sold in Canada. GARDASIL®9, a vaccine (injection/shot) indicated for individuals 9 through 45 years of age for the prevention of infection caused by the Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 and the following diseases associated with the HPV types included in the vaccine: cervical cancer (cancer of the lower end of the uterus or womb), vulvar (the outside of the female genital area) and vaginal cancers, anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58, genital warts (condyloma acuminata) caused by HPV types 6 and 11, abnormal and precancerous cervical lesions (changes in cells of the cervix that have a risk of turning into cancer) as found in a Pap test caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, abnormal and precancerous vaginal, vulvar (outside of the female genital area) and anal lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.


These diseases have many causes. Most of the time, these diseases are caused by nine types of HPV: HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58. GARDASIL®9 only protects against diseases caused by these nine types of HPV. People cannot get HPV or any of these diseases from GARDASIL®9.

The effectiveness of GARDASIL®9 against oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, is based on the effectiveness of GARDASIL® and GARDASIL®9 to prevent persistent infection and anogenital disease caused by HPV types covered by the vaccine.

HPV=human papillomavirus.

## PERSISTENT HPV INFECTION CAN LEAD TO CERTAIN HPV-RELATED CANCERS AND DISEASES

HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 48 are responsible for approximately:



**70% of certain head and neck cancers** – such as throat and back of mouth cancers. Symptoms can include a lump or a sore in the head and neck area that does not heal, a sore throat that does not go away, white or red patches in the mouth

Nearly **100% of cervical cancer cases** – symptoms can include abnormal vaginal bleeding, pain during intercourse, increased vaginal discharge, pain in the pelvic area or lower back

**74% of vaginal or 25% of vulvar cancer cases** – often show no signs. Can cause itchiness or burning, pain in the pelvic area, abnormal vaginal bleeding, difficulty urinating or painful intercourse

**80–90% of anal cancer cases** – symptoms can include anal bleeding, difficulty passing stools, pain or lumps, itching or discharge

**Over 90% of genital warts are caused by HPV types 6 & 11** – small, cauliflower-like growths that may itch or burn. They can be raised or flat, and grow alone or in clusters



In 2012, oropharyngeal cancer was **the most common HPV-related cancer** in Canada. There were 1,335 cases of oropharyngeal cancer, followed by 1,300 cases of cervical cancer and 475 cases of anal cancer.



In 2012, it was reported that the incidence of HPV-related oropharyngeal cancer was at least **4.5X higher in males** than females (n=1335; 6.4 cases/100,000 in men).\*

\* For HPV types 6, 11, 16, and 18-related, persistent infection, CIN (any grade), or external genital lesions, efficacy in men 27-45 was inferred from efficacy data in women 24-45. For HPV types 6 and 11 in boys and men who were PCR negative and seronegative at baseline, efficacy against penile/perineal/perianal intraepithelial neoplasia grades 1/2/3 penile/perineal/perianal cancer was not demonstrated.

**Both men and women should visit a doctor for regular health exams if they think they are at risk of contracting HPV.**


**There is no screening test for HPV in men.** Men can be examined by their doctor for genital warts caused by HPV and signs of HPV-related cancers.

**For individuals with a cervix, a Pap test is a simple screening method that detects cell changes in the cervix.** Regular Pap tests are the best way to find abnormal cervical cells early and treat them before they develop into cervical cancer. **The majority of abnormal Pap tests are caused by HPV.** GARDASIL®9 does not remove the need for cervical cancer screening; women should still get routine cervical cancer screening.

**TALK TO YOUR HEALTHCARE  
PROFESSIONAL ABOUT  
HPV PREVENTION.**

## ADMINISTRATION OF GARDASIL®9

If you're aged 18-45 and eligible, **consider getting vaccinated** with GARDASIL®9 to help protect yourself against certain HPV-related cancers and diseases. GARDASIL®9 is used for individuals 9-45 years of age.



### 1<sup>ST</sup> DOSE

You and your healthcare provider choose a date.

Date:



### 2<sup>ND</sup> DOSE

**2 months after 1<sup>st</sup> dose** (not earlier than 1 month after the 1<sup>st</sup> dose). Alternatively, in individuals aged 9 through 14, between 5 and 13 months after 1<sup>st</sup> dose.

Date:



### 3<sup>RD</sup> DOSE

**6 months after 1<sup>st</sup> dose** (not earlier than 3 months after the 2<sup>nd</sup> dose)

Date:

All 3 doses should be given **within a 1-year period**. For individuals aged 9 through 14, GARDASIL®9 may be given in 2 separate doses. Talk to your healthcare professional for more information.

For individuals aged 9 through 14, if the 2<sup>nd</sup> dose is given earlier than 5 months after the 1<sup>st</sup> dose, a 3<sup>rd</sup> dose should always be given.

**Make sure to get the complete vaccine series: this will help you get the full benefits of GARDASIL®9.**

**If the person getting GARDASIL®9 misses a dose, tell the doctor or healthcare professional, so they can decide when to give the missed dose.**

## PUBLIC AND PRIVATE COVERAGE OF GARDASIL®9



You may have **private health insurance** through work or school that covers vaccination with GARDASIL®9. Speak to your insurance company or visit our consumer website to learn more.

There are also **provincially-funded vaccination programs** which vary by province or territory and by age. So, talk to your healthcare professional about government coverage or reimbursement, and visit our consumer website **GARDASIL9.ca** to learn more about provincially-funded coverage.

If you have a drug benefit wallet card, simply present your card to a pharmacist along with the **Drug Identification Number (DIN) for GARDASIL®9 (02437058)** and ask if you are covered.



## HPV IS ONE OF THE **MOST COMMON SEXUALLY TRANSMITTED INFECTIONS (STIs)** IN CANADA

GARDASIL®9 helps protect you against 9 HPV types in the vaccine that can lead to certain HPV-related cancers and diseases. GARDASIL®9 can be administered in individuals 9 through 45 years of age.

### FACT 1



**BEING IN A MONOGAMOUS  
RELATIONSHIP DOES NOT PROTECT  
YOU FROM HPV INFECTION.**

You can get the virus at any point in your life that you are sexually active. Anyone who has **ever had sexual contact** with another person can get HPV – even skin-to-skin sexual activity without penetration. You can spread the virus without knowing you are infected because **you may not have any visible symptoms**. GARDASIL®9 is not indicated to reduce transmission of HPV.

### FACT 2



**CONDOMS MAY NOT BE ENOUGH  
TO PROTECT YOU AGAINST HPV.**

A condom can only protect the area it covers, but **HPV can still be contracted through skin-to-skin contact** beyond the genital area the condom is covering. That said, using a condom is a great way to reduce your risk of HPV infection and help protect you against other STIs.

### FACT 3



**EVEN IF YOU'VE ALREADY HAD AN  
HPV INFECTION, YOU CAN STILL  
BENEFIT FROM HPV VACCINATION.**

If you're already infected with one type of HPV contained in the vaccine, GARDASIL®9 will help protect you against the other eight types. GARDASIL®9 helps prevent certain cancers and diseases caused by some types of HPV but will not treat them. It does not protect the person getting vaccinated from HPV types that he/she may already have.

**Ask your healthcare  
professional about  
GARDASIL®9 to determine if  
it is suitable for you.**

**TALK TO YOUR HEALTHCARE PROFESSIONAL  
ABOUT GARDASIL®9**

GARDASIL®9 does not treat HPV infection, cancers and diseases and may not protect everyone who gets vaccinated. It does not protect the person getting GARDASIL®9 from a disease caused by other types of HPV, other viruses or bacteria and from HPV types that he/she may already have; but most people do not have all types contained in the vaccine. As with other vaccines, GARDASIL®9 may cause some side effects and allergic reactions. The most common side effects seen are pain, swelling, redness, itching, bruising, bleeding, a lump where the shot is given, headache, fever, nausea, dizziness, tiredness, diarrhea, abdominal pain and sore throat. This is not a complete list of side effects; for any unexpected effects while taking GARDASIL®9, contact your doctor or pharmacist. GARDASIL®9 is not recommended for use in pregnant women. Women should still get routine cervical cancer screening. Women who become pregnant before completion of the vaccine series should complete their vaccination schedule after childbirth. If you are breastfeeding, talk to your doctor or healthcare professional. Fainting can happen after getting an HPV vaccine. Signs of an allergic reaction may include difficulty breathing, wheezing (bronchospasm), hives and rash. Vaccination with GARDASIL®9 does not remove the need for screening for cervical, vulvar, vaginal, anal, and certain head and neck cancers, such as throat and back of mouth cancers. Contact your doctor or healthcare professional to determine if GARDASIL®9 is a suitable option for you.

For complete information about the benefits and risks of GARDASIL®9, visit [https://www.merck.ca/static/pdf/GARDASIL-9-CL\\_E.pdf](https://www.merck.ca/static/pdf/GARDASIL-9-CL_E.pdf).

Scan here to visit our consumer website **GARDASIL9.ca** for more information about HPV, GARDASIL®9, insurance/coverage, and to find a vaccination site near you.

